Moderna Inc (WBO:MRNA)
€ 38.03 -0.48 (-1.25%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 53/100

Moderna Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 12:00PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thank you for joining us for Day 2 of the Goldman Sachs Healthcare Conference. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to be joined by Moderna. With us, we have Stephane Bancel, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Stephane, thank you so much for joining us. And to start here, a question on your modalities. You have established 2 modalities or 2 verticals out of the 6 right now, prophylactic vaccines, systemic secreted and cell surface therapeutics as core. And can you remind us what this means and speak to the biological and technology risks that remain in all your exploratory modalities, and the steps needed to derisk these verticals on the forward.

Stephane Bancel
Moderna, Inc. - CEO & Director

Great. Good morning, Salveen, and thank you for the invitation. So maybe let me

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot